Published in

Elsevier, Heart Rhythm, 9(12), p. 1963-1971, 2015

DOI: 10.1016/j.hrthm.2015.06.007

Links

Tools

Export citation

Search in Google Scholar

Association of pretreatment with angiotensin-converting enzyme inhibitors with improvement in ablation outcome in atrial fibrillation patients with low left ventricular ejection fraction

Journal article published in 2015 by Sanghamitra Mohanty, Prasant Mohanty, Chintan Trivedi, Carola Gianni ORCID, Rong Bai, John David Burkhardt, Joseph G. Gallinghouse, G. J. Gallinghouse, Rodney P. Horton, Javier E. Sanchez, Patrick M. Hranitzky, Amin Al-Ahmad, Shane Bailey, Luigi Di Biase, Andrea Natale
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

BACKGROUND Angiotensin-converting enzyme inhibitors (ACEIs) reduce the incidence of atrial fibrillation (AF). OBJECTIVE The purpose of this study was to assess the impact of upstream ACEI therapy on postablation AF recurrence and hospitalization in patients with low left ventricular ejection fraction (LVEF). METHODS Three hundred forty-five consecutive patients undergoing first AF ablation with low LVEF (45% undergoing first AF ablation were included for a secondary analysis to evaluate the effect of ACEI treatment in normal ejection fraction. In group 1, ACEI therapy started >= 3 months before ablation and continued through follow-up. RESULTS Baseline characteristics were similar except for hypertension, which was significantly more prevalent in ACEI+ (71 /0 vs 51%, P